| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
Methicillin-resistant Staphylococcus aureus (MRSA) is a common pathogenic bacterium that causes nosocomial and community-acquired infections. MRSA infection can cause severe illness not only in immunocompromised patients but also in healthy people. Therefore, the understanding the pathogenesis and developing novel therapeutic option are of important. We have focused on the association between bacterial gene and clinical phenotype on MRSA infection. We revealed that the bacterial genotype affects the clinical characteristics of MRSA infection. Moreover, The frequency of gene mutations on resistant gene loci were gradually decreased along with the increased sensitivity of beta-lactam antibiotics. Then, we found that D-Serine inhibits the attachment and biofilm formation of MRSA by reducing the expression of the related genes. These results highlight the association of gene mutation with phenotype of infection.
|
